



SAFETY DATA SHEET

Revision date: 16-May-2016

Version: 4.1

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Phenytoin Sodium Capsules (25, 30mg, or 50mg)

Trade Name: Dilantin®; Epanutin®

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for seizures and epilepsy.

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B
Carcinogenicity: Category 2

Label Elements

Signal Word: Danger
Hazard Statements: H351 - Suspected of causing cancer
H360D - May damage the unborn child

Precautionary Statements: P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations



SAFETY DATA SHEET

Material Name: Phenytoin Sodium Capsules (25, 30mg, or 50mg)

Page 2 of 9

Revision date: 16-May-2016

Version: 4.1

Other Hazards

No data available

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Phenytoin Sodium	630-93-3	211-148-2	Acute Tox. 4 (H302) Carc. 2 (H351) Repr. 1B (H360D)	16
Magnesium Stearate	557-04-0	209-150-3	Not Listed	*
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Confectioner's sugar	MIXTURE	Not Listed	Not Listed	*
Lactose	63-42-3	200-559-2	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

SAFETY DATA SHEET

Material Name: Phenytoin Sodium Capsules (25, 30mg, or 50mg)

Revision date: 16-May-2016

Page 3 of 9

Version: 4.1

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Phenytoin Sodium

Pfizer OEL TWA-8 Hr: 400 µg/m³

Magnesium Stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³

Lithuania OEL - TWA 5 mg/m³

Sweden OEL - TWAs 5 mg/m³

SAFETY DATA SHEET

Material Name: Phenytoin Sodium Capsules (25, 30mg, or 50mg)

Revision date: 16-May-2016

Page 4 of 9

Version: 4.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Talc (non-asbestiform)

ACGIH Threshold Limit Value (TWA)	2 mg/m ³
Australia TWA	2.5 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Belgium OEL - TWA	2 mg/m ³
Bulgaria OEL - TWA	1.0 fiber/cm ³
	6.0 mg/m ³
	3.0 mg/m ³
Czech Republic OEL - TWA	2.0 mg/m ³
Denmark OEL - TWA	0.3 fiber/cm ³
Finland OEL - TWA	0.5 fiber/cm ³
Greece OEL - TWA	10 mg/m ³
	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	0.8 mg/m ³
Lithuania OEL - TWA	2 mg/m ³
	1 mg/m ³
Netherlands OEL - TWA	0.25 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
Poland OEL - TWA	4.0 mg/m ³
	1.0 mg/m ³
Portugal OEL - TWA	2 mg/m ³
Romania OEL - TWA	2 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
	10 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Spain OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	2 mg/m ³
	1 mg/m ³
Switzerland OEL -TWAs	2 mg/m ³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

SAFETY DATA SHEET

Material Name: Phenytoin Sodium Capsules (25, 30mg, or 50mg)

Page 5 of 9

Revision date: 16-May-2016

Version: 4.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Capsule	Color:	White
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Phenytoin Sodium

No data available

Lactose

No data available

Confectioner's sugar

No data available

Magnesium Stearate

No data available

Talc (non-asbestiform)

No data available

Phenytoin

Predicted 7.4 Log D 2.47

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

SAFETY DATA SHEET

Material Name: Phenytoin Sodium Capsules (25, 30mg, or 50mg)

Page 6 of 9

Revision date: 16-May-2016

Version: 4.1

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information in this section describes the hazards of various forms of the active ingredient. The remaining information describes the potential hazards of the individual ingredients.

Long Term:

Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs, gastrointestinal system and liver.

Known Clinical Effects:

The most common adverse effects observed with clinical use of phenytoin are lack of appetite, headache, dizziness, transient nervousness, ataxia, slurred speech, decreased coordination, mental confusion, insomnia, and GI disturbances (nausea, vomiting, and constipation). IV administration has been associated with hypotension and CNS depression. Mild hypersensitivity reactions (skin rashes) are common. Effects on blood-forming organs and the liver have occurred rarely. Other less common effects include swollen lymph nodes, sore mouth and symptoms of dependence/withdrawal. There is an unconfirmed association between the use of anticonvulsants during pregnancy and an increased risk of birth defects. This material has been shown to be secreted in low concentrations in human breast milk.

Acute Toxicity: (Species, Route, End Point, Dose)

Phenytoin Sodium

Mouse Oral LD50 165 mg/kg

Rat Oral LD50 1530mg/kg

Rat IV LD50 90mg/kg

Mouse IV LD 50 98mg/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Phenytoin

Mouse Oral LD50 150 mg/kg

Rat Oral LD50 1635mg/kg

Rat Intravenous LD 50 96mg/kg

Rat IM LD 50 >337mg/kg

Rabbit Oral LD 50 >3000mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Phenytoin

2 Week(s) Rat Oral <3125 ppm/day NOEL Bone marrow

2 Week(s) Mouse Oral <125 ppm/day NOEL Central Nervous System

13 Week(s) Rat Oral 300 ppm/day NOEL None identified

13 Week(s) Mouse Oral 150 ppm/day NOEL Blood forming organs, Gastrointestinal system, Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Phenytoin

Embryo / Fetal Development Mouse Oral 75 mg/kg/day NOEL Maternal toxicity, Fetotoxicity, Teratogenic

SAFETY DATA SHEET

Material Name: Phenytoin Sodium Capsules (25, 30mg, or 50mg)

Page 7 of 9

Revision date: 16-May-2016

Version: 4.1

11. TOXICOLOGICAL INFORMATION

Embryo / Fetal Development	Mouse	Oral	45 mg/kg/day	NOEL	Teratogenic
Embryo / Fetal Development	Rabbit	Oral	50 mg/kg/day	NOEL	Fetotoxicity, Teratogenic
Embryo / Fetal Development	Monkey	Oral	10 mg/kg/day	NOEL	Fetotoxicity, Teratogenic
Embryo / Fetal Development	Mouse	Subcutaneous	<12.5 mg/kg/day	NOEL	Maternal Toxicity, Fetotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Phenytoin

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
<i>In Vitro</i> Chromosome Aberration	Chinese Hamster Ovary (CHO) cells	Negative
<i>In Vitro</i> Chromosome Aberration	Human Lymphocytes	Negative
<i>In Vivo</i> Sister Chromatid Exchange	Human Lymphocytes	Positive
<i>In Vivo</i> Mitotic Spindle Assay	Human Lymphocytes	Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Phenytoin

2 Year(s)	Male Rat	Oral, in feed	50 mg/kg/day	NOEL	Benign neoplasms, Skin
2 Year(s)	Mouse	Oral, in feed	25 mg/kg/day	NOEL	Benign tumors, Liver
2 Year(s)	Female Mouse	Oral, in feed	60 ppm	LOAEL	Liver, neoplasms
2 Year(s)	Female Rat	Oral, in feed	240 ppm	NOAEL	Not carcinogenic

Carcinogen Status: See below

Phenytoin Sodium

IARC: Group 2B (Possibly Carcinogenic to Humans)
NTP: Reasonably Anticipated To Be A Human Carcinogen

Talc (non-asbestiform)

IARC: Group 3 (Not Classifiable)

Phenytoin

IARC: Group 2B (Possibly Carcinogenic to Humans)
NTP: Reasonably Anticipated To Be A Human Carcinogen

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided. See aquatic toxicity data, below:

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Phenytoin

<i>Hyallela azteca</i> (Freshwater Amphipod)	OPPTS	LC50	96 Hours	18 mg/L
<i>Daphnia magna</i> (Water Flea)	TAD	EC50	48 Hours	>39 mg/L
<i>Pimephales promelas</i> (Fathead Minnow)	OPPTS	LC50	96 Hours	>23 mg/L

SAFETY DATA SHEET

Material Name: Phenytoin Sodium Capsules (25, 30mg, or 50mg)

Page 8 of 9

Revision date: 16-May-2016

Version: 4.1

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Persistence and Degradability: No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Phenytoin

Predicted 7.4 Log D 2.47

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Phenytoin Sodium

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

carcinogen initial date 1/1/88

Inventory - United States TSCA - Sect. 8(b)

Present

Australia (AICS):

Present

EU EINECS/ELINCS List

211-148-2

Confectioner's sugar

SAFETY DATA SHEET

Material Name: Phenytoin Sodium Capsules (25, 30mg, or 50mg)

Page 9 of 9

Revision date: 16-May-2016

Version: 4.1

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Lactose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-559-2

Magnesium Stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

Talc (non-asbestiform)

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	238-877-9

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Carcinogenicity-Cat.2; H351 - Suspected of causing cancer
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 16-May-2016
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet